Allergic rhinitis market seen reaching $19.58 billion by 2030

The Business Research Company says the global allergic rhinitis market will grow from $16.28 billion in 2026 to $19.58 billion by 2030. The forecast points to stronger demand for immunotherapy, personalized care, online pharmacies and better testing as air pollution and allergy prevalence rise.

Why it matters: - The allergic rhinitis market is expanding as more people seek diagnosis and treatment for allergy symptoms linked to pollen, dust mites, mold spores and animal dander. - Growth in the market matters for drugmakers, diagnostic providers and pharmacy channels because it tracks broader demand for allergy care. - Environmental pressures such as air pollution and climate change are adding to the need for treatment.

What happened: - The Business Research Company released its Allergic Rhinitis Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Oct. 30, 2026. - The report estimates the global allergic rhinitis market at $16.28 billion in 2026, up from $15.69 billion in 2025. - The report projects the market will reach $19.58 billion by 2030, representing a 4.7% compound annual growth rate. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period.

The details: - Historical growth was supported by higher allergy awareness, greater exposure to environmental allergens, wider use of antihistamines and corticosteroids, growth in hospital pharmacy networks and better skin testing. - Forecast growth is expected to come from immunotherapy innovation, personalized allergy management, increased use of online pharmacies, and improvements in IgE RAST and blood testing technologies. - The report also points to continued growth in the worldwide prevalence of allergic rhinitis, broader use of nasal corticosteroids and antihistamines, expanded e-commerce distribution and stronger diagnostic capabilities. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report says the company’s 2026 research includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards and market hotspots infographics. - The source defines allergic rhinitis as inflammation of the nasal passages caused by allergens and notes common symptoms including sneezing, nasal congestion, nose itchiness and sore throat. - Treatment typically uses allergy medications in multiple dosage forms to reduce symptoms and improve quality of life. - U.S. Environmental Protection Agency data cited in the release showed about 66 million tons of pollutants were emitted into the U.S. atmosphere in 2023. - The release says those environmental conditions are contributing to market expansion. - Contact information listed in the release includes Saumya Sahay and marketing@tbrc.info, along with regional phone numbers for the Americas, Asia and Europe. - The release also links to a free sample of the report and the full market report.

Between the lines: - The forecast suggests allergic rhinitis is becoming a more data-driven treatment market, with diagnostics, personalization and digital distribution gaining importance alongside traditional medications. - The regional split signals mature demand in North America and faster expansion potential in markets where urbanization and healthcare access are still rising. - The emphasis on pollution and climate change shows the report framing allergic rhinitis as both a medical and environmental growth story.

What's next: - The report expects continued adoption of immunotherapy, nasal corticosteroids and antihistamines through 2030. - Online pharmacy sales and diagnostic testing tools are expected to play a larger role in how patients access allergy care. - The Asia-Pacific market is positioned for the fastest growth as allergy prevalence and healthcare access increase.

The bottom line: - Allergic rhinitis is moving from a steady-growth category to a broader platform for allergy treatment, diagnostics and digital pharmacy expansion.